EUROFLOW™ ANTIBODY PANELS

Atypical lymphocytes
Sustained monocytosis Suspicion of lymphoma Monoclonal component non-IgM
High suspicion of Splenomegaly
Unexplained cytopenia Monoclonal component Localization in “small cell number” Bone lesions
acute leukemia Lymphocytosis
Unexplained eosinophilia simples, e.g. CSF, vitrous biopsies BM plasmacytosis
Lymph node enlargement

ALOT LST SST PCST

Acute Leukemia Orientation Tube Lymphoid Screening Tube Small Sample Tube First Tube of PCD
Pacific PerCP- APC- Pacific PerCP- APC- Pacific PerCP- APC-
OC515™* FITC PE PE-Cy7 APC OC515™* FITC PE PE-Cy7 APC OC515™* FITC PE PE-Cy7 APC
Blue™ Cy5.5 C750™* Blue™ Cy5.5 C750™* Blue™ Cy5.5 C750™*

CD20 CD8 CD56 CD19 CD8 CD56 CD3

CyCD3 CD45 CyMPO CyCD79a CD34 CD19 CD7 SmCD3 and CD45 and and CD5 and CD3 CD38 CD20 CD45 and and CD4 CD19 and CD38
CD4 SmIgλ SmIgκ TCRγδ SmIgλ SmIgκ CD14 Other Clonal

Reactive/Polyclonal Clonal/Aberrant Reactive/Polyclonal

AML/MDS B-CLPD PCD

Acute Myeloid Leukemia / Myelodysplastic Syndromes B-Cell Chronic Lymphoproliferative Disorders Plasma Cell Dyscrasias
Pacific PerCP- APC- Pacific PerCP- APC- Pacific PerCP- APC-
Tube OC515™* FITC PE PE-Cy7 APC Tube OC515™* FITC PE PE-Cy7 APC Tube OC515™* FITC PE PE-Cy7 APC
Blue™ Cy5.5 C750™* Blue™ Cy5.5 C750™* Blue™ Cy5.5 C750™*
AML/MDS Limited
1 CD45 CD138 CD38 CD56 β2micro CD19 CyIgκ CyIgλ
1 HLA-DR CD45 CD16 CD13 CD34 CD117 CD11b CD10 CD20 CD8 CD56 CD19
1 and CD45 and and CD5 and CD3 CD38 2 CD45 CD138 CD38 CD28 CD27 CD19 CD117 CD81
2 HLA-DR CD45 CD35 CD64 CD34 CD117 CD300e CD14
CD4 SmIgλ SmIgκ TCRγδ Tube 1: Detection of aberrant and clonal plasma cells. Tube 2: Complementary phenotypic
3 HLA-DR CD45 CD36 CD105 CD34 CD117 CD33 CD71 Aim
2 CD20 CD45 CD23 CD10 CD79b CD19 CD200 CD43 characterization and evaluation of markers with potential prognostic impact.
4 HLA-DR CD45 NuTdT CD56 CD34 CD117 CD7 CD19
Complete
AML
3 CD20 CD45 CD31 CD305 CD11c CD19 SmIgM CD81
5 HLA-DR CD45 CD15 NG2 CD34 CD117 CD22 CD38
CD42a 4 CD20 CD45 CD103 CD95 CD22 CD19 CD185 CD49d
6 HLA-DR CD45 and CD203c CD34 CD117 CD123 CD4
5 CD20 CD45 CD62L CD39 HLA-DR CD19 CD27 -
CD61 Monitoring of MM
Tube 1: LST tube; Detection of B-CLPD. Tube 2: Identification of CLL vs other B-CLPD cases, when
AML-M7
Aim combined with LST. Tube 3, 4, and 5: Further subclassification of non-CLL BCLPD (e.g. HCL, MCL,
7 HLA-DR CD45 CD41 CD25 CD34 CD117 CD42b CD9 FL, MZL, LPL, DLBCL and other B-CLPD).
Tube 1: Diagnosis and subclassification of AML and PNH especially focused on neutrophilic
lineage. Tube 2: Diagnosis and subclassification of AML and PNH especially focused on
monocytic lineage. Tube 3: Diagnosis and subclassification of AML especially focused
Aim
on erythroid lineage. Tube 4: Aberrant expression of lymphoid associated markers and
abnormal lymphoid maturation. Tube 5: Aberrant expression of markers; Detection of stem MM MRD
cells. Tube 6: Diagnosis and subclassification of AML especially focused on megakaryocytic, Multiple Myeloma Minimal Residual Disease
basophilic, and plasmacytoid dendritic lineages. Tube 7: Characterization of AML-M7,
mastocytosis. PerCP- APC-
Tube BV-421 BV-510 FITC PE PE-Cy7 APC
Cy5.5 C750™*

1 CD138 CD27 CD38 CD56 CD45 CD19 CD117 CD81

2 CD138 CD27 CD38 CD56 CD45 CD19 CyIgκ CyIgλ

Aim MM MRD: Bone marrow MRD measurement in MM.

T-ALL NK-CLPD
T-Cell Acute Lymphoblastic Leukemia NK-Cell Chronic Lymphoproliferative Disorders
Pacific PerCP- APC- Pacific PerCP- APC-
Tube OC515™* FITC PE PE-Cy7 APC Tube OC515™* FITC PE PE-Cy7 APC
Blue™ Cy5.5 C750™* Blue™ Cy5.5 C750™*
1 CyCD3 CD45 NuTdT CD99 CD5 CD10 CD1a SmCD3 1 CD2 CD45 CD7 CD26 CD3 CD56 CD5 CD19 CTPC
2 CyCD3 CD45 CD2 CD117 CD4 CD8 CD7 SmCD3
2 CD16 CD45 CD57 CD25 CD3 CD56 CD11c CD19
Circulating Tumour Plasma Cell
3 CyCD3 CD45 TCRγδ TCRαβ CD33 CD56 CyTCRβ SmCD3 PerCP- APC-
3 HLA-DR CD45 CyPerforin CyGranzymeB CD3 CD56 CD94 CD19 Tube BV-421 BV-510 FITC PE PE-Cy7 APC
4 CyCD3 CD45 CD44 CD13 HLA-DR CD45RA CD123 SmCD3 Cy5.5 C750™*
Tube 1: Detection of aberrant NK cell phenotype. Tube 2: Detection of aberrant NK cell phenotype.
Tube 1: Diagnosis of T-ALL, classification of T-ALL, and determine the maturation stage of Aim 1 CD138 CD27 CD38 CD56 CD45 CD19 CD117 CD81
Tube 3: Detection of aberrant NK cell phenotype; Assessment of cytotoxic effector phenotype.
arrest; Identification of LAP markers.Tube 2: Diagnosis of T-ALL, classification of T-ALL, and
Aim determine the maturation stage of arrest; Identification of LAP markers.Tube 3: Diagnosis 2 CD138 CD27 CD38 CD56 CD45 CD19 CyIgκ CyIgλ
of T-ALL and determine the maturation stage of arrest; Identification of LAP markers. Tube
4: Subclassification of T-ALL. Aim CTPC: Monitoring of Circulating Tumour Plasma Cells in peripheral blood

BCP-ALL T-CLPD
B-Cell Precursor Acute Lymphoblastic Leukemia T-Cell Chronic Lymphoproliferative Disorders
Pacific PerCP- APC- Pacific PerCP- APC-
Tube OC515™* FITC PE PE-Cy7 APC Tube OC515™* FITC PE PE-Cy7 APC
Blue™ Cy5.5 C750™* Blue™ Cy5.5 C750™*
REFERENCES:
1 CD20 CD45 CD58 CD66c CD34 CD19 CD10 CD38 1 CD4 CD45 CD7 CD26 CD3 CD2 CD28 CD8
1. van Dongen JJM, et al. on behalf of the EuroFlow Consortium (EU-FP6, LSHB-
SmIgM CT-2006-018708). EuroFlow antibody panels for standardized n-dimensional flow
2 CD4 CD45 CD27 CD197 CD3 CD45RO CD45RA CD8
2 SmIgκ CD45 CyIgμ CD33 CD34 CD19 and SmIgλ
cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia.
CD117 3 CD4 CD45 CD5 CD25 CD3 HLA-DR CyTCL1 CD8 2012 Sep; 26:1908–75.
3 CD9 CD45 NuTdT CD13 CD34 CD19 CD22 CD24
4 CD4 CD45 CD57 CD30 CD3 - CD11c CD8
CD15 2. Theunissen P, et al. Standardized flow cytometry for highly sensitive MRD measurements in
4 CD21 CD45 and NG2 CD34 CD19 CD123 CD81 5 CD4 CD45 CyPerforin CyGranzymeB CD3 CD16 CD94 CD8
B-cell acute lymphoblastic leukemia. Blood. 2016 Jun; 129(3): 347-57.
CDw65
6 CD4 CD45 - CD279 CD3 - - CD8
Tube 1: Diagnosis and classification of BCP-ALL; Detection of LAP markers; Detection of 3. Flores-Montero J, et al. Next Generation Flow for highly sensitive and standardized detection
phenotypes associated with molecular aberrations. Tube 2: Diagnosis and classification Tube 1: Phenotypic characterization; Identification of Sézary syndrome. Tube 2: Phenotypic
characterization; Assessment of maturation stage. Tube 3: Phenotypic characterization;
of minimal residual disease in multiple myeloma. Leukemia. 2017 Oct; 31(10):2094-103.
of BCP-ALL. Tube 3: Diagnosis and classification of BCP-ALL; Detection of phenotypes
Aim Identification of T-PLL. Tube 4: Phenotypic characterization; Cytotoxic phenotype and
associated with molecular aberrations; Detection of LAP markers. Tube 4: Subclassification Aim
of BCP-ALL; Detection of LAP markers; Detection of phenotypes associated with molecular identification of anaplastic T-cell lymphoma. Tube 5: Phenotypic characterization; Assessment 4. Sanoja-Flores L, et al. Next generation flow for minimally-invasive blood characterization of
aberrations. (LAP= Leukemia-associated phenotypes). of cytotoxic associated phenotypes; Identification of T-LGL. Tube 6: Identification of lymphomas MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).
derived from follicular helper T cells (angioimmunoblastic T-cell lymphomas). Blood Cancer J. 2018 Nov; 8(12):117.

Monitoring of BCP-ALL

BCP-ALL MRD
ALOT (ref. CYT-ALOT), LST (ref. CYT-LST), SST (ref. CYT-SST), PCST (ref. CYT-PCST),
BCP-ALL Minimal Residual Disease BCP-ALL MRD (ref. CYT-BCP-ALL-MRD), MM MRD (ref. CYT-MM-MRD), CTPC (ref. CYT-CTPC)
Pacific PerCP- APC-
Tube OC515™* FITC PE PE-Cy7 APC Cytognos offers antibodies and pre-mixed combinations according to EuroFlow™ guidelines.
Blue™ Cy5.5 C750™*
CD66c Mature B cell core (ref. CYT-MBC-CORE), Percursor B cell core (ref. CYT-PBC-CORE)
* Or equivalent fluorochrome
1 CD20 CD45 CD81 and CD34 CD19 CD10 CD38
CD123

2 CD20 CD45 CD81

CD73
and CD34 CD19 CD10 CD38
EuroFlow™ databases available in Infinicyt™ for LST, ALOT, MM MRD and CTPC www.cytognos.com | www.euroflow.org
CD304